Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageNeogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, insect control products and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through veterinarians, retailers, livestock producers and animal health product distributors.
In the company’s own words · 10-K filed Jul 30, 2026 · SEC EDGAR
Business segments
Jun 2026 · $116.6MThe company’s own SEC segment disclosure.
- Bacterial And General Sanitation$46.7M40%
- Service$26.5M23%
- Natural Toxins And Allergens$19.2M16%
- Veterinary Instruments And Disposables$15.8M14%
- Genomics Services$6.6M6%
- Life Sciences$1.8M2%
Neogen Corporation (NEOG) reported revenue of $211M in Q3 2026 (quarter ended Feb 28, 2026), down 4.4% from the same quarter a year earlier. That came with a gross margin of 47% and net loss of $17M. For the full year FY2025, revenue was $895M (−3.2% year on year) and net income −$1.09B. Its largest product in Jun 2026 was Bacterial And General Sanitation at $47M, 40% of the disclosed total, ahead of Service at 23%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.